Get the Stockscreener App
0.6623
10.19%
-0.0729
After Hours:
.66
-0.0023
-0.35%
X 4 Pharmaceuticals Inc stock is traded at $0.6623, with a volume of 39.01M.
It is down -10.19% in the last 24 hours and down -18.30% over the past month.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$0.7352
Open:
$0.8121
24h Volume:
39.01M
Relative Volume:
8.29
Market Cap:
$117.49M
Revenue:
-
Net Income/Loss:
$-101.17M
P/E Ratio:
-1.1225
EPS:
-0.59
Net Cash Flow:
$-96.57M
1W Performance:
+27.51%
1M Performance:
-18.30%
6M Performance:
-21.40%
1Y Performance:
-17.72%
1-Day Range:
$0.63
$0.8142
1-Week Range:
$0.43
$0.8142
52-Week Range:
$0.2612
$1.60
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
0.6623 | 117.49M | 0 | -101.17M | -96.57M | -0.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Stock Market Movers Today • Top Gainers & Losers - Benzinga
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition - Star Local Media
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Adam S. Mostafa Sells 74,773 Shares - MarketBeat
Mark Baldry Sells 29,159 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock - MarketBeat
Insider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Sells 22,258 Shares of Stock - MarketBeat
X4 Pharmaceuticals CFO Mostafa Adam S. sells $33,946 in stock - MSN
x4 pharmaceuticals CEO sells shares worth $34,718 By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals COO Mary DiBiase sells $10,094 in stock By Investing.com - Investing.com Nigeria
x4 Pharmaceuticals CCO Mark Baldry sells $13,241 in stock - Investing.com
x4 Pharmaceuticals chief commercial officer sells $13,241 in stock - Investing.com
X4 Pharmaceuticals' chief medical officer sells $5,284 in stock - Investing.com
x4 pharmaceuticals CEO sells shares worth $34,718 - Investing.com
x4 Pharmaceuticals CCO Mark Baldry sells $13,241 in stock By Investing.com - Investing.com UK
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixaforlicenced to Norgine for commercialisation in Europe. - Yahoo Finance
X4 Pharma stock gains as lead drug under EU review (XFOR) - Seeking Alpha
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome - Yahoo Finance
Barclays PLC Buys 183,861 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - Quantisnow
January 2025's Top US Penny Stocks To Consider - Simply Wall St
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis - Business Wire
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price - Simply Wall St
EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow
Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow
EVP Research Swayze Eric converted options into 19,160 shares and sold $235,678 worth of shares (7,176 units at $32.84), increasing direct ownership by 35% to 45,670 units (SEC Form 4) - Quantisnow
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
X4 Pharmaceuticals (NASDAQ:XFOR) Earns Buy Rating from HC Wainwright - Defense World
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - Scrip
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine - Research Tree
X4 Pharmaceuticals (NASDAQ:XFOR) Receives Buy Rating from HC Wainwright - MarketBeat
Jane Street Group LLC Increases Stock Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
X4 Pharmaceuticals Partners with Norgine for Mavorixafor Expansion - TipRanks
X4 Pharmaceuticals, Inc. and Norgine Pharma UK Limited Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - Marketscreener.com
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - Yahoo Finance
StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
Brookline Capital Management Estimates XFOR FY2024 Earnings - Defense World
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS - PR Newswire
Brokers Set Expectations for XFOR FY2024 Earnings - MarketBeat
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Fragile X Syndrome Clinical and Non-Clinical Studies, Key - openPR
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Geode Capital Management LLC Trims Stock Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Jagsonpal Pharmaceuticals record date for 1:2.5 stock split today - The Economic Times
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - Quantisnow
Chief Operating Officer Mancini Marianna was granted 66,200 shares and sold $2,317,599 worth of shares (54,215 units at $42.75), increasing direct ownership by 3% to 374,134 units (SEC Form 4) - Quantisnow
Chief Financial Officer Zante Greg sold $2,150,595 worth of shares (50,309 units at $42.75) and was granted 66,200 shares, increasing direct ownership by 11% to 165,259 units (SEC Form 4) - Quantisnow
SEC Form 4 filed by Director Macartney Lawson - Quantisnow
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations - Star Local Media
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program - Yahoo Finance
Prescription Drug Costs | Pros, Cons, Debate, Arguments, Economy, Laws, Government, & Regulation - Britannica
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
5.46%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):